Rintatolimod (Ampligen(®)) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program

SIMPLE SUMMARY: Survival of patients with locally advanced and metastatic pancreatic cancer remains poor after standard care with FOLFIRINOX. It is not known whether treatment with rintatolimod, a TLR-3 agonist, would improve progression-free survival. We investigated the immunomodulatory effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: el Haddaoui, Hassana, Brood, Rianne, Latifi, Diba, Oostvogels, Astrid A., Klaver, Yarne, Moskie, Miranda, Mustafa, Dana A., Debets, Reno, van Eijck, Casper H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946630/
https://www.ncbi.nlm.nih.gov/pubmed/35326528
http://dx.doi.org/10.3390/cancers14061377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946630/
https://www.ncbi.nlm.nih.gov/pubmed/35326528
http://dx.doi.org/10.3390/cancers14061377

Ejemplares similares